Document:

Exhibit
10.10

CONSULTING
AGREEMENT

THIS
CONSULTING AGREEMENT (this “Agreement”) is made and entered into effective as of July 9, 2018 (the “Effective
Date”), by and among Enochian Biosciences, Inc. (the “Company”), its wholly owned subsidiary, Enochian
Biopharma, Inc. (“Enochian”) and G Tech Bio LLC, a California limited liability company (the “Consultant”).

WHEREAS,
on the Effective Date, the parties desire to enter into this Agreement pursuant to which the Consultant will provide the Consulting
Services (as defined herein).

NOW,
THEREFORE, in consideration of the mutual promises, covenants and promises contained herein, and intending to be legally bound
hereby, the Company and the Consultant do hereby agree and covenant as follows:

1.                 
Consulting Services. The Consultant shall
provide the Company and Enochian with the services described on Schedule A attached hereto (the “Consulting Services”).

2.                 
Payment; Reimbursements.

(a)              
Consultant shall be compensated according to
the “Schedule of Compensation” set forth on Schedule B attached hereto.

(b)              
All normal and customary business expenses incurred
by the Consultant under this Agreement shall be paid by the Consultant, and reimbursed by the Company or paid by the Company upon
the request of the Consultant; provided, however, that the Consultant shall not receive reimbursements for business expenses in
excess of $50.00 without prior written approval of the Company.

3.                 
Independent Contractor Relationship. All
services rendered hereunder by the Consultant shall be as an independent contractor. Any persons employed by the Consultant shall
be deemed conclusively as employees of the Consultant, and they shall at all times be under the Consultant’s direction and
control, and they shall be bound to the same terms as Consultant under this Agreement and under that certain Non-Disclosure and
Confidentiality Agreement between the Company and Consultant dated of even date herewith (the “Non-Disclosure and Confidentiality
Agreement”). The Consultant shall have the full power, authority, and discretion to select the means, manner, and method
of performing the services hereunder without detail, control or direction from the Company or its officers or directors. Neither
the Consultant, nor its manager, members or any individual employed by the Consultant shall be considered employees of the Company
or Enochian for any purposes and they shall not be entitled to participate in any employee benefit plans sponsored or maintained
by the Company.

4.                 
Term; Termination; Future Services.

(a)              
The Consultant shall commence providing services
on the Effective Date, and shall continue to do so until the date this Agreement is terminated in accordance with Section 4(b)
below (the “Termination Date”).

    	 	1	 

     

    

 

(b)              
This Agreement is terminable at any time by either
party upon three (3) months prior written notice to the other party, effective as of the date set forth in such notice; provided
that Company may terminate Consultant immediately for “cause”, which shall mean any manager, member or employee of
Consultant’s (i) indictment for, conviction of or pleading of guilty or nolo contendere to, a felony or any crime
involving moral turpitude; (ii) violation of any an order, sentence, plea or settlement agreement or adjudication (each, an “Order”)
of a court competent jurisdiction, including such Orders existing as of the Effective Date; (iii) breach of any obligations of
confidentiality provided herein or any unauthorized disclosure of any Company trade secrets or other confidential information;
(iv) performance of any material act of theft, embezzlement, fraud, malfeasance, dishonesty or misappropriation of the Company’s
property; or (v) material breach of this Agreement or any other material agreement with the Company or a material violation of
the Company’s code of conduct or other written policy; provided further that any “cause” shall only apply to
an occurrence after the Effective Date. Sections 3, 7, 8, 9, 10, 11, 13 and 15 shall survive termination of this Agreement for
any reason. For purposes of this Agreement, email notification shall be deemed to be written notice.

(c)              
For the avoidance of doubt, any services performed
by the Consultant for the Company or Enochian following the Termination Date shall not be deemed as Consulting Services governed
by this Agreement.

5.                 
Consultant Responsible for Taxes. The
Consultant agrees to accept exclusive liability for the payment of taxes due on any amounts paid under this Agreement.

6.                 
Non-Disclosure and Confidentiality Agreement.
The Consultant agrees to continue to be bound by the Non-Disclosure and Confidentiality Agreement.

7.                 
Ownership. 

(a)       All
information, technology, ideas, concepts, improvements, discoveries and inventions, whether patentable or not, which are conceived,
made, developed, discovered, or acquired and/or reduced to practice by Consultant, solely or in combination with others, or which
are disclosed or made known to Consultant, individually or in combination with others, during the Term and which are related to
the Company’s and/or Enochian’s business, technology, intellectual property, products, processes, procedures and/
or services, and/or that Consultant has been or may be directed to undertake, investigate or experiment with by or for the Company
and/or Enochian and/or that Consultant has or may become associated with in work, investigation or experimentation by or for the
Company and/or Enochian in performing the services under this Agreement or in contemplation hereof (including all such information
relating to corporate opportunities, research, development, marketing, processing, financial and sales data, pricing and trading
terms, evaluations, opinions, interpretations, acquisition prospects, the identity of clients or customers or their requirements,
the identity of key contacts within the client or customers’ organizations or within the organization of acquisition prospects,
or marketing and merchandising techniques, prospective names and marks) (collectively, “Inventions”) are and shall
be the sole and exclusive property of the Company and/or Enochian. Moreover, all drawings, memoranda, notes, records, files, correspondence,
manuals, models, specifications, computer programs, maps and all other writings or materials of any type embodying any of such
Inventions, information, ideas, concepts, improvements, discoveries and inventions are and shall be the sole and exclusive property
of the Company and/or Enochian. For the avoidance of confusion, Consultant acknowledges that any intellectual property, including
patents or provisional patents, arising from or related to the Consulting Services shall be “Inventions” as defined
herein. Consultant also agrees to assign (or cause to be assigned) without any further payment by the Company or Enochian and
hereby assigns fully to the Company and/or Enochian all Inventions and any copyright, patent, trade secret, and mask work rights
and/or other intellectual property rights relating to all Inventions.

    	 	2	 

     

    

 

(b)       In
particular, Consultant hereby specifically assigns and transfers to the Company and/or Enochian all of Consultant’s worldwide
right, title and interest in and to all such Inventions, information, ideas, concepts, improvements, discoveries and/or inventions,
and any United States or foreign applications for patents, inventor’s certificates or other industrial rights that may be
filed thereon, and applications for protection and/or registration of Inventions, such names and/or marks. During the Term and
thereafter, Consultant shall assist the Company and/or Enochian and their nominees at all times in the protection of such Inventions,
information, ideas, concepts, improvements, and/or discoveries or inventions, both in the United States and all foreign countries,
including the execution of all lawful oaths, applications, specifications and all assignment documents and other instruments requested
by the Company and/or Enochian or their nominees in connection with the preparation, prosecution, issuance or enforcement of any
applications for United States or foreign letters patent, and any other document application for the protection and/or registration
of such Inventions, names and/or mark, including the disclosure to the Company and/or Enochian of all pertinent information and
data with respect to all Inventions that the Company and/or Enochian may deem necessary in order to apply for and obtain such
rights and in order to assign and convey to the Company and/or Enochian, their successors, assigns and nominees the sole and exclusive
right, title and interest in and to all Inventions, and any copyright, patent, trade secret, and/or mask work rights or other
intellectual property rights relating to all Inventions. Consultant also agrees that Consultant’s obligation to execute
or cause to be executed any such instrument or papers shall continue after the termination of this Agreement.

(c)       Moreover,
if during the Term, Consultant creates any original work of authorship fixed in any tangible medium of expression which is the
subject matter of copyright (such as reports, videotapes, written presentations, computer programs, drawings, maps, architectural
renditions, models, manuals, brochures or the like) related to the Company’s and/or Enochian’s business, technology,
intellectual property, products, processes or services, whether such work is created solely by Consultant or jointly with others,
the Company and/or Enochian shall be deemed the co-author of such work if the work is prepared by Consultant in the scope of the
Consulting Services hereunder; or, if the work is not prepared by Consultant within the scope of the Consulting Services hereunder
but is specially ordered by the Company and/or Enochian as a contribution to a collective work, as a part of any written or audiovisual
work, as a translation, as a supplementary work, as a compilation or as an instructional text, then the work shall be considered
to be work made for hire and the Company and/or Enochian shall be the co-author of the work. Both during the Term and thereafter,
Consultant shall assist the Company and/or Enochian and their nominees, at any time, in the protection of the Company’s
and/or Enochian’s worldwide right, title and interest in and to the work and all rights of copyright therein, including
the execution of all formal assignment documents requested by the Company and/or Enochian or their nominees and the execution
of all lawful oaths and applications for registration of copyright in the United States and foreign countries; provided, however,
that Consultant shall be compensated by the Company and/or Enochian at a reasonable hourly rate for assistance given after the
end of the Term.

    	 	3	 

     

    

 

(d)       Return
of Company Property. Upon the termination of this Agreement for any reason (or at any time prior thereto at the Company’s
and/or Enochian’s request), Consultant shall return all property belonging to the Company and/or Enochian or their Affiliates
(including any Company and/or Enochian and/or Affiliate-provided laptops, computers, cell phones, wireless electronic mail devices
or other equipment, or materials, information, documents or property, in any form, belonging to the Company and/or Enochian and/or
an Affiliate).

(e)
       Pre-Existing Materials. Subject to Section 8(a), Consultant agrees that
if, in the course of performing the Consulting Services, Consultant incorporates into any Invention developed under this Agreement
any pre-existing invention, improvement, development, concept, discovery or other proprietary information owned by Consultant
or in which Consultant has an interest, (i) Consultant will inform Company and/or Enochian, in writing while incorporating such
invention, improvement, development, concept, discovery or other proprietary information into any Invention and (ii) the Company
and/or Enochian and Consultant shall enter into a nonexclusive, perpetual, irrevocable, worldwide license to the Company and/or
Enochian to make, have made, modify, use and sell such item as part of or in connection with such Invention on terms, including
the payment to Consultant of appropriate royalties, which are mutually agreeable by both parties. Consultant will not incorporate
any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any
Invention without Company’s and/or Enochian’s prior written permission.

(f)       Attorney-in-Fact.
Consultant agrees that, if the Company or Enochian is unable because of Consultant’s unavailability, mental or physical
incapacity, or for any other reason, to secure Consultant’s signature for the purpose of applying for or pursuing any application
for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company
or Enochian in Section 8(a), then Consultant hereby irrevocably designates and appoints the Company and its duly authorized
officers and agents as Consultant’s agent and attorney-in-fact, to act for and on Consultant’s behalf to execute and
file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright
and mask work registrations with the same legal force and effect as if executed by Consultant.

(g)
       Personal License Back. During the term of this Agreement, Enochian will grant
the Consultant the nonexclusive, royalty-free, personal right to assign to any of its members who are medical doctors the right
to use the intellectual property controlled by Enochian relating to HIV treatment in humans solely to treat patients in the personal
practice of medicine by such members (the “Right to Use”).

8.                 
Non-Solicitation. The Consultant agrees
that during the term of this Agreement and for a period of one year after the Termination Date, the Consultant will not encourage
or solicit any employee or consultant of the Company or Enochian to leave the Company or Enochian for any reason.

    	 	4	 

     

    

 

9.                 
Arbitration, Choice of Law. This Agreement
shall be deemed to have been executed and delivered within the State of California, and the rights and obligations of the parties
hereunder shall be construed and enforced in accordance with, and governed by, the laws of the State of California without regard
to principles of conflict of laws. In the event of a dispute, the parties agree to arbitrate all claims related to this Agreement
before a single arbitrator in Los Angeles County, California under the Rules of the American Arbitration Association.

10.             
Severability. If any provision of this
Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of the
Agreement which can be given effect without the invalid provisions or applications and to this end, the provisions of this Agreement
are declared to be severable.

11.             
Advice of Counsel. In entering into this
Agreement, the parties recognize that this Agreement is a legally binding contract and acknowledge and agree that each party has
had the opportunity to consult with legal counsel of its choice.

12.             
Entire Agreement. This Agreement, the
License Agreement, and the Non-Disclosure and Confidentiality Agreement, together with all schedules and Exhibits made a part
hereof and thereof constitute and contain the entire agreement and final understanding between the parties covering the services
to be provided by the Consultant. It is intended by the parties as a complete and exclusive statement of the terms of their agreement,
and they supersede all prior negotiations and agreements, proposed or otherwise, whether written or oral, between the parties
concerning Consulting Services. Any representation, promise or agreement not specifically included in this Agreement shall not
be binding upon or enforceable against either party. This Agreement may be modified only with a written instrument duly executed
by each of the parties. No person has any authority to make any representation or promise on behalf of any of the parties not
set forth herein and this Agreement has not been executed in reliance upon any representations or promises except those contained
herein.

13.             
No Assignment. The Consultant shall not
assign either in whole or in part any of the Consultant’s duties or responsibilities hereunder without the written consent
of the Company, and any attempt of assignment transfer or delegation without such consent shall be void.

14.             
Written Reports. The Consultant, when
directed, shall provide written reports to Company’s Chief Executive Officer with respect to the services rendered hereunder.

15.             
Headings. Headings are used only for ease
of reference and are not controlling.

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the date first above written.

 

	 DANDRIT
                                         BIOTECH USA, INC.:

 

By/s/
Eric Leire

Name:
Dr. Eric Leire

Title:
Chief Executive Officer

Notice
Address:

Century
City Medical Plaza

2080
Century City East

Suite
906

Los
Angeles, CA 90067

 

Email:
el@enochianbio.com

With
a copy to:

clayton.parker@klgates.com

	

G
TECH BIO, LLC:

 

By
/s/ W. Anderson Wittekind 

Name:
W. Anderson Wittekind

Title:
Manager

Notice
Address:

 

Century
City Medical Plaza

2080
Century City East

Suite
710

Los
Angeles, CA 90067

 

Email:
andersonwittekind@gmail.com

With
a copy to:

 
	ENOCHIAN
        BIOPHARMA, INC.:

 

By/s/
Eric Leire

Name:
Dr. Eric Leire

Title:
Chief Executive Officer

Notice
Address:

Century
City Medical Plaza

2080
Century City East

Suite
906

Los
Angeles, CA 90067

 

Email:
el@enochianbio.com

With
a copy to:

clayton.parker@klgates.com

 	 

    	 	6Exhibit 10.11

 

 

 

Private and Confidential

 

December 28, 2018

 

By Email

Luisa Puche

318 NE 104th street

Miami Shores, FL 33138

luisa@puchegroup.com

 

Dear Luisa:

 

Further to our recent discussions in respect
of your employment with Enochian BioSciences, Inc. (“Enochian” or the “Company”), we are
delighted to offer you the full-time position of Chief Financial Officer (“CFO”) effective January 7, 2019.
The highlights and terms of your employment are outlined below.

 

		1.	Position and Responsibilities:

 

Your employment with Enochian will commence
on January 7, 2019. Your responsibilities will include any and all duties assigned to you as CFO. You will report to the
Chief Executive Officer (“CEO”) and the Audit Committee of the Company’s Board of Directors.

 

You agree that you shall at all times conscientiously
perform all of the duties and obligations assigned to you to the best of your ability and experience and in compliance with law.
You must use your best efforts to promote the interests of Enochian and to devote your full business time and energies to the business
and affairs of Enochian and the performance of your job duties.

 

		2.	Salary: 

 

You will receive an annual base salary of $200,000.00
payable in bi-weekly (every two weeks) installments of $7,692.31 subject to applicable withholding and other lawful
deductions.

 

		3.	Bonus:

 

You will be eligible for a cash bonus beginning
at the end of the fiscal year ending June 30, 2019, with an annual bonus target of 40% (“Target”) of your base
salary ($80,000). Once the bonus plan is finalized there is a possibility to earn a determined maximum Target dependent upon corporate
and personal performance goals determined by the Compensation Committee of the Board of Directors (“Compensation Committee”).

 

		4.	Equity Incentives:

 

Subject to the approval of the Compensation
Committee, you will be eligible for a hiring grant of 60,000 Stock Options and 15,000 shares of Restricted Stock (the “Grant”);
such Grant to be made in accordance with the 2014 Equity Incentive Plan. Each equity award will vest in three equal annual installments
of 33% per year, with the first 33% being fully vested on the first anniversary of your date of hire.

 

The specific mix and number of shares
granted in future years as part of the annual equity grant program will be determined annually in line with the Company’s
equity plan(s) and at the discretion of the Board of Directors.

    	 	1	 

     

    

 

		5.	Performance Review

 

You will be eligible for a performance and
salary review in February 2020 (retroactive to the anniversary of your hire date, meaning retroactively applied from January 7,
2020).

 

		6.	Benefits: 

 

You will be eligible to receive all the usual
benefits offered to employees at your level including participation in Company’s sponsored medical, dental, and insurance
programs subject to the eligibility, terms, and conditions of such plans, if any. The Company reserves the right
to modify the benefits it offers and terms of coverage from time to time at the Company’s sole discretion.

		7.	Paid Time Off:

 

You shall earn four (4) weeks (20 business
days) of paid time off (“PTO”) per calendar year. PTO shall be taken at times mutually agreeable to you and
the Company and otherwise pursuant to applicable workplace policies. You shall further be entitled to paid holidays and authorized
(paid and unpaid) leaves in accordance with the policies of the Company then in effect for its senior executives.

 

	Restrictive Covenant Agreement and
Protection of Confidential Information:

It is the Company’s policy to
have employees in your position sign the Company’s Employee Non-Disclosure, Non-Solicitation, and Non-Competition Agreement.
This offer is contingent on you executing this Agreement, a copy of which is attached hereto as Exhibit A.

		9.	At Will Employment:

 

Your employment with Enochian is “at
will,” in that either you or Enochian has the right to terminate the employment relationship at any time, with or without
cause and with or without notice. This status may only be altered by written agreement, which is specific as to all material terms
and is signed by an authorized officer of Enochian. This offer letter does not, and is not, intended to create either an express
and/or implied contract of employment with Enochian for a definitive term of employment.

 

	Termination:

a.                   
Definitions. For purposes of this Section 10:

i.     
“Cause” shall mean: (i) your failure to materially perform and discharge
your duties and responsibilities under this Agreement after receiving written notice and allowing you thirty (30) days to cure
such failure, if so curable, (provided, however, that after one such notice has been given to you during your employment, the Company
is no longer required to provide time to cure subsequent failure); (ii) breach of Section 11 of this offer letter or of your restrictive
covenants with the Company; (iii) misconduct which, in the opinion and sole discretion of the Company, is injurious to the Company;
(iv) conviction or pleading nolo contendere to a felony or misdemeanor involving the personal dishonesty or moral turpitude; (v)
engagement in illegal drug use or alcohol abuse, which prevents you from performing your duties in any manner; (vi) any misappropriation,
embezzlement, or conversion of the Company’s or any of its parent’s, subsidiary’s or affiliate’s property;
(vii) willful misconduct or breach of fiduciary duty by you in respect of your duties or obligations; (viii) your failure to materially
perform and discharge the duties and responsibilities with respect to goals or objectives periodically provided to you by the Company
after receiving written notice and allowing you thirty (30) days to cure such failure, if so curable, (provided, however, that
after one such notice has been given to you during your employment, the Company is no longer required to provide time to cure subsequent
failure); (ix) your inability to perform the essential functions of your, with or without reasonable accommodation, for an aggregate
period in excess of ninety (90) days during the previous twelve (12) months, due to a physical or mental illness, disability, or
condition, or your; or (x) your death.

    	 	2	 

     

    

ii.     
“Change in Control” shall mean (a) the consummation of a merger or consolidation
of the Company with or into another entity, (b) the dissolution, liquidation or winding up of the Company, (c) the closing of the
sale, lease, transfer or other disposition of all or substantially all of the Company’s assets in one transaction or a series
of related transactions or (d) the closing of the transfer of the Company’s outstanding securities, in one transaction or
a series of related transactions, to a person or group of affiliated persons if, after such closing, such person or group of affiliated
persons would hold a majority of the voting power of the capital stock of the Company. The foregoing notwithstanding, a merger
or consolidation of the Company does not constitute a “Change in Control” if immediately after the merger or consolidation
a majority of the voting power of the capital stock of the continuing or surviving entity, or any direct or indirect parent corporation
of the continuing or surviving entity, will be owned by the persons who were the Company’s stockholders immediately prior
to the merger or consolidation in substantially the same proportions as their ownership of the voting power of the Company’s
capital stock immediately prior to the merger or consolidation. 

iii.     
“Good Reason” shall mean (i) a material diminution in your authority, duties,
or responsibilities; (ii) a material diminution in your annual base salary as in effect immediately prior to such diminution, other
than in connection with a general diminution in Enochian’s compensation levels and in amounts commensurate with the percentage
diminution of other Enochian employees of comparable seniority and responsibility; or (iii) if applicable, a material breach by
Enochian of an agreement with you pursuant to which you provide services to Enochian. No violation described in clauses (i) through
(iii) above shall constitute Good Reason unless you have given written notice to Enochian specifying the applicable clause and
related facts giving rise to such violation within sixty (60) days after the occurrence of such violation and Enochian has not
remedied such violation to your reasonable satisfaction within thirty (30) day of its receipt of such notice.

b.                  
Termination by the Company without Cause or Termination by Employee for Good Reason.
In the event that the Company terminates your employment without Cause or you terminate your employment for Good Reason, you will
be entitled to six (6) months’ salary as severance and COBRA eligibility (“Severance”) provided you execute
a mutually agreeable release waiving any and all claims against the Company other than the obligations set forth in such release
or in a final severance agreement and any applicable revocation period with respect to such release has expired (a “Release”).
In the event of termination under this Subsection 10(b), you will not be entitled to severance, pro-rated bonuses or other
post-termination payment except the severance as provided in this Subsection 10(b).

c.                   
Termination for Cause or Termination without Good Reason. In the event you are terminated:
(i) for cause at any time; or (ii) you voluntarily leave your employment without Good Reason at any time, no severance, no pro-rated
bonuses or other post-termination payment shall be due or payable by the Company except solely base salary and such payments as
may have been accrued but not yet paid prior to such termination.

d.                  
Termination Upon Change in Control. In the event that at any time during your employment
after July 7, 2019 the Company terminates your employment without Cause or you terminate your employment for Good Reason during
the twelve (12) months following a Change in Control, upon the execution of a Release you will be entitled to (i) Severance (ii)
a pro-rated cash payment based on the Target for the year in which such termination occurs and (iii) the immediate vesting of the
Grant. 

	Prior Agreements:

This offer of employment is contingent
upon your acknowledgement and representation to the Company that (a) there are no restrictions, agreements, or understandings whatsoever
to which you are a party which would prevent or make unlawful your execution of this offer letter or employment with the Company,
(b) that your execution of this offer letter and employment hereunder shall not constitute a breach of any contract, agreement
or understanding, oral or written, to which you are a party or by which you are bound; and (c) that you are free and able to execute
this offer letter and be employed by the Company. A written or oral notice or complaint that these representations are not true
and/or that you are violating a restrictive covenant or an agreement not to disclose confidential information from a prior employer
shall subject you, at the Company’s sole discretion, to immediate termination for cause.

    	 	3	 

     

    

 

		12.	General Contingencies:

 

This offer is contingent upon verification
of eligibility to work in the United States. In order to comply with the Immigration Reform and Control Act of 1986, you will need
to provide proof of U.S. citizenship or the right to work in the United States on your first day of employment.

This offer is also contingent upon satisfactory
results of background investigation, reference checks, and pre-employment alcohol and drug tests.

 

		13.	Governing Law:

 

If any provision of this offer letter
should be wholly or partially invalid, unenforceable or unlawful, then this employment offer shall be severable with respect to
the provision in question (to the extent that it is invalid, unenforceable, or unlawful), and the remaining provisions of this
offer of employment shall continue in full force and effect. This offer of employment shall be interpreted in accordance with the
laws of the State of Florida. This offer of employment constitutes the entire understanding between the parties and shall supersede
any and all other understandings, oral or written. No addition to, or modification of, this employment letter shall be of any force
or effect unless in writing and signed by or on behalf of both parties. By executing and delivering this offer letter, you irrevocably
submit to and accept the exclusive jurisdiction of the courts in the State of Florida and waive any objection (including any objection
to venue or any objection based upon the grounds of forum non conveniens) which might be asserted against the bringing of any such
action, suit or other legal proceeding in such courts.

		14.	Employment Manual:

 

During your employment with Enochian, you will
be required to abide by Enochian’s code of conduct, policies, and procedures as set forth in Enochian’s employee manual
or as otherwise communicated to you in writing.

 

		15.	SEC Compliance:

 

For purposes of Securities and Exchange Commission
(“SEC”) reporting, you will be deemed an “executive officer” and are subject to the rules and requirements
of Section 16 of the Securities Exchange Act of 1934. You understand and agree that you will keep the terms and conditions of your
employment confidential until such time as your employment is publicly disclosed as required by applicable SEC rules and regulations.

 

    	 	4	 

     

    

 

 

		16.	Acceptance:

 

To accept this offer, please sign and date
this page, keep a copy for your records, and return a copy to me. Please also sign and date the attached agreement and return the
signed agreement to my attention.

 

We are excited about this opportunity to work
with you to build the Enochian brand and business. We are extremely confident that your employment with us will prove mutually
beneficial and we look forward to having you join our winning team!

 

 

 

 

Please let me know if you have any questions.

Very truly yours,

 

 

 /s/
James Sapirstein____________

James Sapirstein,

Chairman of the Compensation Committee
of Enochian BioSciences, Inc.

 

 

I accept your offer of employment as set forth
in this employment offer letter. I understand that my employment is “at will” and that either you or I can terminate
my employment at any time, for any reason. No oral commitments have been made concerning my employment.

 

 

/s/ Luisa Puche       Date: 12/28/2018

Luisa Puche

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]